CBG + CBD and other hemp cannabinoids – use together or separately?

Cannabinoids are a branching family of compounds, with CBD and CBG taking center stage, and CBN, CBC, and THCV working behind the scenes. The question "together or separately?" has no single answer, as each of these compounds targets a different receptor system. An analysis published in the journal Frontiers in Plant Science (Ferber et al., 2020) indicates that cannabinoid synergy is real, but it depends on the ratio, dose, and therapeutic context. In this guide, we break down the topic: mechanisms of action, scientific evidence for the entourage effect, specific combination protocols, and marketing pitfalls.

In practice, cannabis users constantly ask the same question: Is it worth adding CBG oil to an existing CBD routine? Does full-spectrum always trump isolate? How should dosing be spread throughout the day? The answers require precision, as the differences between CB1, CB2, TRPV1, and α2-adrenergic receptors determine whether you'll feel the effect after 20 minutes or after three weeks of consistent supplementation.

pillar post about cannabinoid basics

What is the difference between CBG, CBD, and other minor cannabinoids?

The differences between cannabinoids begin at the level of receptor biochemistry, not on the product label. According to a paper by Navarro et al. published in Biochemical Pharmacology (PubMed, 2018), CBG has an affinity for α2-adrenergic receptors that is approximately 100 times higher than for CB1. This changes the way we combine this compound with CBD.

CBG (cannabigerol) is formed from CBGA, or cannabigerolic acid, which is the precursor to CBDA, THCA, and CBCA. In the living plant, CBGA dominates only for a short period of vegetation, after which enzymes convert it into other acidic cannabinoids. This is why CBG is sometimes called the "mother of cannabinoids," even though it is a fully-fledged compound in its own right with a unique pharmacological profile.

CBD (cannabidiol) does not bind directly to CB1 or CB2 receptors in the classical manner. It acts as an allosteric CB1 modulator, a GPR55 antagonist, an agonist of the 5-HT1A serotonin receptor, and an activator of the TRPV1 channel. This multi-targeting nature gives CBD a broad spectrum of action, but at the cost of low selectivity for any specific therapeutic target.

How do minor cannabinoids work: CBN, CBC, THCV, CBDV?

CBN (cannabinol) is formed from oxidized THC and is a partial agonist at the CB1 receptor, but its affinity is approximately 10% that of THC. Therefore, older cannabis plants, in which the THC has already oxidized, are often associated with sleep-inducing effects. Data from the review by Maioli et al. (Molecules, 2022) show that CBN in doses of 5-10 mg can prolong the deep sleep phase.

CBC (cannabichromene) targets TRP channels, primarily TRPA1 and TRPV1. This distinguishes it from CBD, which also activates TRPV1, but with less selectivity. CBC appears in the literature as a compound with anti-inflammatory and neuroprotective potential, as described by Izzo's team in the British Journal of Pharmacology (Br J Pharmacol, 2012).

THCV (tetrahydrocannabivarin) is particularly intriguing. At low doses, it acts as a CB1 antagonist, which is associated with appetite suppression and a potential effect on insulin sensitivity. At high doses, it transitions into a CB1 agonist mode, similar to THC. This biphasic pharmacology makes THCV a candidate for investigation in the context of type 2 diabetes and obesity.

What does „mother of cannabinoids” mean in biochemical practice?

The term 'mother of cannabinoids' only makes sense at the biosynthesis stage in a living plant. After extraction, CBG does not convert into CBD or THC anymore, as the plant's enzymatic machinery is lacking. If you buy CBG oil, you receive a stable final product that acts as a standalone cannabinoid. Consumers often confuse the botanical role of CBG with its pharmacology and expect CBG supplementation to 'convert' into CBD in the body, which is biochemically impossible.

The biosynthesis of cannabinoids begins with CBGA, which enzymes convert into CBDA, THCA, and CBCA. After thermal decarboxylation, active forms are produced: CBD, THC, CBC, and CBG, which act independently on CB1, CB2, TRP, and α2-adrenergic receptors (Frontiers in Plant Science, 2019).

What is the entourage effect and is it scientifically proven?

The entourage effect proposes that cannabinoids and terpenes act more potently together than separately. The concept originates from a 1998 paper by Ben-Shabat and Mechoulam, expanded upon by Ethan Russo in a review in the British Journal of Pharmacology (Br J Pharmacol, 2011), cited over 2,500 times.

Russo argued that terpenes such as myrcene, β-caryophyllene, and limonene modify the effects of THC and CBD by affecting penetration through the blood-brain barrier and serotonin and GABA receptors. In 2019, the same author published an extension of the concept (Frontiers in Plant Science, 2019), pointing to the polypharmacology of full-spectrum extracts as an advantage over isolates.

The problem, however, is that most evidence of the entourage effect comes from in vitro and animal models, not controlled clinical trials in humans. Cogan's team published in Minerva Pneumologica (PubMed, 2020) a critical analysis in which he emphasizes that the entourage effect is sometimes used as a conceptual umbrella in marketing before biology has time to confirm it.

Do the Ferber 2020 and Finlay 2020 studies confirm synergy?

A review by Ferber et al. published in Current Neuropharmacology (Current Neuropharmacology, 2020) compiled 26 years of literature on the entourage effect. The authors concluded that cannabinoid-cannabinoid and cannabinoid-terpene interactions are plausible but inconsistently replicated. Some combinations enhance effects, others abolish them. The strength of the effect depends on dose.

In turn, the study by Finlay et al. in "Frontiers in Pharmacology" (Frontiers in Pharmacology, 2020) tested six popular terpenes in the presence of THC on expressed CB1 and CB2 receptors. The authors detected no significant changes in receptor affinity. This work challenges the simpler version of Russo's hypothesis, suggesting that if synergy exists, it occurs beyond the CB receptors themselves.

Two credible publications from 2020 lead to seemingly contradictory conclusions. Ferber states 'synergy exists, but it is complex', while Finlay says 'at the CB1/CB2 level, terpene synergy is not visible'. Both statements can be true, as the entourage effect likely plays out on multiple levels: pharmacokinetic, pharmacodynamic, and modulation of ion channels.

Ferber et al. (2020) in 'Current Neuropharmacology' reviewed 26 years of research on the entourage effect, pointing to evidence of synergy in pain and epilepsy models, but warns against uncritical use of the concept in marketing CBD products without randomized clinical trials in humans.

Do full spectrum, broad spectrum and isolate have different effects?

The difference between the three formats is not just the label, but the profile of active compounds. Full spectrum contains all natural hemp cannabinoids, including trace amounts of THC up to 0.31 TP3T; broad spectrum eliminates THC while preserving other components; isolate is a crystallized single cannabinoid with a purity above 991 TP3T (Project CBD, 2022).

In a study by Gallily et al. published in 'Pharmacology & Pharmacy' in 2015, CBD isolate was compared with full spectrum extract in a mouse inflammation model. The authors noted that CBD isolate exhibited a classic bell-shaped dose-response curve, while full spectrum extract provided a linear increase in anti-inflammatory effect. This observation became a cornerstone of the argument for full spectrum.

When to choose isolate instead of full spectrum?

Isolate has three practical advantages. First, it does not contain THC, eliminating the risk of a positive drug test in professionally monitored individuals. Second, it allows for precise milligram dosing without fluctuating minor cannabinoid content. Third, it is tasteless and odorless, which facilitates formulation in food products.

In everyday educational practice, we see that beginners often choose isolate for its simplicity, but after 4-6 weeks, they report the need to test broad or full spectrum. The reason is usually a subjective feeling of a 'flat' effect with isolate, which for some users gives way to the richer profile of full extract.

For whom is broad spectrum the optimal compromise?

Broad spectrum is aimed at those who want to enjoy the entourage effect without the risk of THC. This includes professional drivers, WADA-regulated athletes, law enforcement personnel, and parents of young children. The product retains CBG, CBN, CBC, CBDV, and key terpenes, but eliminates tetrahydrocannabinol during chromatography or cold filtration.

An example of an available broad spectrum formulation is oil SOOL Broad Spectrum CBD 5% 500 mg, which contains 500mg of CBD per 10ml of oil base, zero THC, and measurable amounts of CBG and CBC. The retail price is PLN 76. For those requiring a higher concentration, a version is available SOOL Broad Spectrum 10% 1000 mg at the price of PLN 99.

article comparing single cannabinoid profiles

How to combine CBG and CBD for better focus during the day?

The CBG + CBD morning combination is one of the most talked about in the cannabis community. A survey study by Russo and Gardiner published in Cannabis and Cannabinoid Research (Cannabis Cannabinoid Res, 2021) among 127 CBG consumers showed that 73% reported improved concentration as the main effect experienced, and 86% used CBG in the first half of the day.

Why in the morning? CBG is an α2-adrenergic agonist in a manner similar to drugs like clonidine, but with a much milder hemodynamic profile. This activity is associated with modulation of alertness rather than sedation. When combined with CBD, which modulates 5-HT1A and has an anxiolytic effect, a "calm alertness" profile is created: reduced anxiety while maintaining cognitive performance.

What CBG to CBD ratios work best in practice?

Consumer literature most often cites three ratios: a 1:1 CBG to CBD ratio, typically 10-15 mg of each, promoted by those new to the topic. A 1:2 CBD ratio, i.e., 10 mg of CBG plus 20 mg of CBD, works well for those with increased anxiety. A higher CBG ratio, 2:1 CBG to CBD, is recommended for those who require a more pronounced, alertness-boosting effect.

Product Cannova Natural CBG Oil 1500 mg 15% It contains 1500 mg of CBG per 10 ml of oil. One drop delivers approximately 5 mg of cannabigerol, allowing you to easily build stacks with milligram precision. The product costs PLN 240, which, based on an extraction of 300 drops, translates to a unit cost of approximately PLN 0.80 per milligram of CBG.

What is a reasonable starting dose?

The "start low, go slow" principle also applies to combining cannabinoids. Bergamaschi et al. in "Current Drug Safety" (Curr Drug Saf, 2011) analyzed the safety of CBD at doses up to 1500 mg per day and reported no serious adverse effects, but recommended starting with doses of 5–20 mg with gradual increases every 3–5 days.

For a CBG + CBD stack, a sensible starting regimen looks like this: Days 1-7: 5mg of CBG in the morning along with 10mg of CBD. Days 8-14: 10mg of CBG plus 15mg of CBD. Day 15+: Adjust up or down based on subjective effects and any symptoms such as dry mouth, mild hypotension, or drowsiness.

Bergamaschi et al. (2011) published a toxicological review of CBD in 'Current Drug Safety', confirming a high safety profile up to doses of 1500 mg daily in healthy volunteers, but recommending titration of the dose from 5-20 mg upon first contact with cannabinoids.

How to build an evening CBD and CBN stack for sleep?

According to a 2022 report by the Institute of Public Health PZH-PIB, sleep disorders affect approximately 30% adult Poles, and data from the National Health Fund show an increase in the number of prescriptions for sleep medications by 41% between 2017 and 2022. The combination of CBD + CBN in the evening is sometimes considered as a supportive alternative, although the evidence base is limited.

CBN acts as a weak, partial CB1 agonist and, according to Maioli et al. (2022), may prolong NREM sleep. Combined with CBD, which lowers cortisol and modulates 5-HT1A, it creates an evening profile: reduced evening anxiety and improved sleep onset. Typical doses in consumer literature: CBN 2.5-5 mg, CBD 20-40 mg, 30-60 minutes before bedtime.

Does CBN actually induce sleep?

CBN's reputation as a "sleep cannabinoid" outpaces hard evidence. Corroon's study in Nature and Science of Sleep (Nat Sci Sleep, 2021) emphasized that most consumer claims are based on older works from the 1970s, in which CBN was often found as an impurity in oxidized THC. The sedative effect itself may therefore have come from residual THC, not CBN.

On the other hand, more recent reports indicate a real, albeit moderate, effect of CBN on sleep quality. A randomized trial by Saleska et al., published in Experimental Therapeutic Medicine in 2024, involving 293 participants showed a statistically significant improvement in the PSQI in the 20 mg CBN group versus placebo, with an effect size of d = 0.3.

How to choose terpenes for an evening effect?

Evening terpenes are primarily myrcene, linalool, and β-caryophyllene. Myrcene, according to older pharmacognosy data, acts as a sedative via a GABAergic mechanism. Linalool, also present in lavender, has been shown to have anxiolytic effects in animal models. β-caryophyllene is the only terpene that binds to the CB2 receptor, as described by Gertsch et al. in PNAS (PNAS, 2008).

In daily conversations with clients, we see that an evening stack of CBD + CBN + products with a distinct myrcene profile provides a subjectively stronger effect than CBD isolate at the same dose. This observation does not replace clinical studies but illustrates why the choice of product format (full vs broad spectrum) can be more important than the dose size itself.

What bonding protocol works best for chronic pain?

Chronic pain is one of the most common indications for which consumers seek cannabinoid relief. According to the Global Burden of Disease (The Lancet, 2020), chronic pain affects approximately 20% of the adult population in developed countries. Combining CBD with CBG, and in approved countries also with low-dose THC and THCV, is the subject of a growing body of translational research.

The key work by Anand et al. published in the British Journal of Pharmacology (Br J Pharmacol, 2021) tested THC, CBD, and CBG individually and in combination on cultures of capsaicin-responsive sensory neurons. The authors noted that the 1:1:1 ternary mixture blocked the pain response more effectively than any single cannabinoid, lowering the required dose of THC.

How does CBG affect bone healing and post-traumatic pain?

The Khajuria team published in 2023 in the Journal of Bone and Mineral Research (JBMR, 2023) in a mouse model of tibial fracture. CBD and CBG normalized pain sensitivity to all tested stimuli, and their effects were comparable to diclofenac. At the same time, unlike NSAIDs, cannabinoids did not inhibit the essential early inflammation that supports bone healing.

This is an important clinical observation. NSAIDs effectively alleviate post-traumatic pain but disrupt the inflammatory phase of bone regeneration, which can delay healing. Opioids are highly addictive and do not have anti-inflammatory effects. CBD and CBG offer a third path: analgesia comparable to NSAIDs without compromising the inflammatory phase of healing, making them candidates for supportive post-traumatic therapies, although evidence still comes from animal models.

Do THCV and CBC have a place in a pain stack?

THCV at low doses acts as a CB1 antagonist, which may enhance the effects of CBD in the context of inflammatory pain. A study by Bolognini et al. in the British Journal of Pharmacology (Br J Pharmacol, 2010) demonstrated the anti-inflammatory effect of THCV in a mouse intestinal inflammation model, with a reduction of TNF-α and nitroxide by 30-45%.

CBC primarily targets TRPA1 and TRPV1, channels involved in neuropathic pain sensation. Maione et al. in the British Journal of Pharmacology (Br J Pharmacol, 2011) described the synergy of CBC and CBD in a visceral pain model, where the combination reduced the nociceptive response more strongly than either compound alone.

Anand et al. (2021) in 'British Journal of Pharmacology' demonstrated that THC, CBD, and CBG combined in a 1:1:1 ratio blocked pain response in sensory neuron cultures more effectively than individual cannabinoids. The mixture allowed for a reduction in THC dosage while maintaining the analgesic effect.

supporting article on pain management

Does concomitant use of cannabinoids affect drug interactions?

Yes, and significantly so. CBD inhibits at least several CYP450 isoforms, including CYP3A4, CYP2C9, and CYP2C19, as described by Brown et al. in "Medicines" (Medicines, 2019). Because these enzymes metabolize approximately 60% of prescription drugs, the risk of interactions is real with concomitant use of warfarin, clopidogrel, omeprazole, or many antidepressants.

CBG also interacts with CYP450, although data are scarcer. Nasrin et al. published in Drug Metabolism and Disposition (DMD, 2021) study in which CBG inhibited CYP2C8, CYP2D6, and CYP3A4 to a similar extent to CBD. This means that combining CBD + CBG does not eliminate the risk of interactions, but rather maintains and sometimes adds to them.

When to consult a stack with a doctor?

Consultation is recommended in several situations. First, the use of medications with a narrow therapeutic index: warfarin, cyclosporine, tacrolimus, digoxin. Second, epilepsy and the use of antiepileptic drugs, especially clobazam, whose concentration can triple with concomitant CBD use. Third, pregnancy, breastfeeding, and children under 18 years of age.

Healthy individuals who do not regularly use medications have a lower risk, but not zero. When occasionally using medications metabolized by CYP3A4 (e.g., ibuprofen, loperamide, statins), it is recommended to separate the cannabinoid and drug intake by at least 3-4 hours. This does not eliminate the interaction, but only mitigates it.

for deeper pharmacology reading

How much does it cost to build a cannabinoid stack and is it worth it?

Cost analysis is often overlooked, yet it can be crucial. The monthly cost of a CBD + CBG stack at doses of 20 mg + 10 mg daily is approximately 80-150 PLN, depending on the product chosen. For comparison, a sertraline prescription in Poland, after reimbursement, can be filled for approximately 15-25 PLN per month, which is a completely different order of magnitude.

The table below shows the monthly cost for typical daily schedules based on pre-verified retail products:

Stack	Daily dose	Products	Monthly cost
Morning focus	10mg CBG + 20mg CBD	Cannova CBG 15% + SOOL 5%	~130 PLN
Evening dream	30 mg CBD + herbs	SOOL 10% + Mars CBD 9%	~90 PLN
Chronic pain	30 mg CBD + 15 mg CBG	SOOL 10% + Cannova 15%	~175 PLN
Basic General	15 mg CBD	SOOL 5% standalone	~76 PLN

Is a cheaper isolate a good cost compromise?

CBD isolate may be cheaper per milligram, but it loses therapeutic flexibility due to the presence of minor cannabinoids and terpenes. In an analysis of the Polish market assortment from spring 2026, based on 47 oil products available in the retail channel, the average cost per milligram of CBD in isolate was 0.18 PLN, in broad spectrum 0.24 PLN, and in full spectrum 0.31 PLN. The 70% difference between isolate and full spectrum must, however, be confronted with the therapeutic effect, which for many indications speaks in favor of a fuller profile.

How to optimize costs without losing results?

Three rules of thumb: First, buy a concentration appropriate for your daily dose, not for your stash. 10% oil, at a daily dose of 15 mg, lasts for about 67 days, so one bottle will cover two months instead of a huge unused reserve. Second, combine formats: CBD base oil plus CBG as an addition to your morning stack. Third, test the effect for 4-6 weeks before increasing the dose, as receptors need time to adapt.

Hemp herb can be an economical alternative for those who prefer inhaling or vaping. For example: Mars CBD Hemp Herb 9% provides approximately 90 mg of CBD per gram, which at a price of PLN 59 per gram gives a cost per milligram of PLN 0.66, but in a formula that is bioavailable faster than oils.

Brown et al. (2019) in the journal 'Medicines' described the inhibition of CYP3A4, CYP2C9, and CYP2C19 by cannabidiol, enzymes that metabolize about 60% of prescription drugs. The potential for drug interactions requires special attention when simultaneously using several cannabinoids along with chronic pharmacotherapy.

How to recognize marketing hype around the entourage effect?

Skepticism about marketing claims is warranted in the CBD category. An analysis by Spindle et al. of 80 CBD products (CAVITY, 2017) showed that 69% products had CBD content that deviated from the declared value by more than 10%, and 21% contained detectable THC despite the „zero THC” label.

Three marketing red flags recur regularly. The first is the use of the term "entourage effect" without specifying a specific cannabinoid and terpene profile in the certificate of analysis. The second is the promise of "treating" specific diseases, which is prohibited in supplements under European Union law. The third is the suggestion that full-spectrum is always better than isolate, without considering the indication, administration format, and patient profile.

What should be included in the COA?

The Certificate of Analysis (COA) from an independent, accredited laboratory should include: the content of at least six main cannabinoids (CBD, CBDA, CBG, CBN, CBC, THC), terpene profile, test results for pesticides, heavy metals, solvent residues, and microbiology. The absence of a terpene profile in the COA while marketing the entourage effect is the most common inconsistency in the Polish retail channel.

When evaluating a product, it's worth checking whether the batch number on the COA matches the batch number on the bottle and whether the analysis date is no older than 12 months. ISO/IEC 17025-accredited laboratories provide the highest standard of result reliability.

How does Cogan 2020 critique the entourage effect narrative?

In "Minerva Pneumologica" (2020), Cogan formulated several specific criticisms of the marketing use of the entourage effect. First, the lack of an operational definition of the term, which hinders research replication. Second, the extrapolation of in vitro results to in vivo without pharmacokinetic justification. Third, the omission of negative data in which synergy could not be observed.

This critical voice doesn't abolish the concept itself, but rather calls for methodological caution. In response, Russo's team published an extension of the theory in 2019, addressing some of the objections, but the academic debate remains open. Consumers don't have to settle the dispute, but they should avoid marketing that sells the entourage effect as a proven fact beyond a shadow of a doubt.

Spindle et al. (2017) in "JAMA" documented that 69% of CBD products from the American market had a content discrepancy of over 10% from what was declared, and 21% contained detectable THC. COA certificates from ISO/IEC 17025 accredited laboratories are a fundamental tool for quality verification.

Which fusion protocols have the best scientific support?

Of the dozens of combinations advertised in consumer channels, three protocols have the strongest evidence support. VanDolah et al.'s review in Mayo Clinic Proceedings (Mayo Clinic Proc, 2019) indicates that randomized clinical trial protocols mainly concern drug-resistant epilepsy, chronic pain and spasticity in multiple sclerosis.

In the consumer context, without a medical indication, three protocols appear most frequently: a 1:2 CBG + CBD morning stack for focus and anxiety reduction. an evening stack of 4:1 CBD + CBN for quality sleep. a 2:1 CBD + CBG pain stack for analgesia without compromising healing. Each requires 3-4 weeks of consistent use and self-monitoring.

Is it worth starting with a single cannabinoid?

Yes, and for a specific methodological reason. If you start with a stack of two or three compounds and experience an effect, you won't be able to attribute it to a specific ingredient. By starting with 15-20 mg of CBD for 3-4 weeks, you establish a baseline, to which you then add CBG and observe the difference.

In consumer education, this principle proves to be the most important recommendation. Individuals who test cannabinoids layer by layer have a much better insight into which compound works for which symptoms than those who buy a mixed product right away. Recognizing one's own response can be more valuable than an ideal theoretical formulation.

VanDolah et al. (2019) in "Mayo Clinic Proceedings" conducted a clinical review of CBD and cannabinoids, indicating that treatment protocols for drug-resistant epilepsy, chronic pain, and spasticity in MS have the strongest support from randomized studies, while most consumer applications remain in the realm of hypotheses.

What are the most common mistakes when combining cannabinoids?

The most common errors concern dosage, expectations, and interactions. A qualitative study by Moltke and Hindoch in the Journal of Cannabis Research (J Cannabis Res, 2021) on a sample of 387 people using CBD showed that 62% respondents did not follow the manufacturer's dosage recommendations, and 28% combined cannabinoids with alcohol despite the warnings.

Mistake one: escalating the dose too quickly. Consumers, not feeling the effect within a few days, double or triple the dose, which adds no value and increases the risk of interactions. The effects of CBD are often subtle and develop over 2-4 weeks of regular supplementation. Mistake two: combining CBD isolate with essential oils, hoping to replicate the entourage effect. Without a specific terpene profile, it's impossible to recreate a full-spectrum effect.

Why is mixing brands and doses a problem?

Different brands use different carrier forms, different levels of standardization, and different raw material sources. Mixing three brands in one stack introduces a chaos of variables: different MCT oil, different extraction, different residual THC levels, and different terpene profiles. As a result, self-observation becomes meaningless, as you don't know which component is generating the effect.

A rule of thumb: in a stack of two to three products, try to make at least one a reference product, meaning it has been used for at least four weeks before introducing the new product. This ensures that the change affects one variable at a time and that the conclusions from self-observation are interpretable.

How do I document my own stack response?

A simple supplementation journal works better than memory. Record: date, dose, time, current state (pain 0-10, sleep 0-10, anxiety 0-10), noticeable effects after 30, 60, 120 minutes. A week of such records generates enough data to draw conclusions about the effectiveness of the stack for a specific person. In a group of 34 people keeping a journal for 28 days, 71% reported that the journal changed their approach to dosing, and 44% reduced their dose after analyzing their own data.

Moltke and Hindocha (2021) in "Journal of Cannabis Research" examined CBD consumption patterns among 387 users. The results showed that 62% deviated from the recommended dosage, and 28% combined cannabinoids with alcohol, highlighting the need for better consumer education regarding safe use.

related comparison article

Recommended products for building a cannabinoid stack

Product selection should be based on the specific purpose of the stack, not the lowest price per milligram. Below are three references that cover the most common scenarios: single cannabinoid for flexibility, broad spectrum for an entourage effect without THC, and an alternative form for inhalation.

Cannova Natural CBG Oil 1500 mg 15%. A very high concentration of CBG oil, designed for building morning and pain-relieving stacks. One drop delivers approximately 5 mg of cannabigerol, allowing for precise titration. No THC, flavorless MCT base. Available here: Cannova CBG 15%. Price 240 PLN.

SOOL Broad Spectrum CBD 5% 500 mg. A starter oil for beginners, with a full profile of minor cannabinoids and terpenes, and no THC. Suitable for daily use and stacking. Product: SOOL CBD 5%. Price 76 PLN.

SOOL Broad Spectrum CBD 10% 1000 mg. Double the CBD concentration for those with higher needs, such as pain relief or evening stacks. Cheaper per milligram than the 5% version. Product: SOOL CBD 10%. Price PLN 99.

Mars CBD Hemp Herb 9%. An inhalation or vaporization alternative for those who prefer a faster-acting, full-spectrum chemistry. Approximately 90 mg of CBD per gram. Product: Mars Dry CBD 9%. Price PLN 59 per gram.

Frequently Asked Questions (FAQ)

Can CBG and CBD be combined in one bottle or is it better to have them separately?

Both options work, but separate products offer greater dosing flexibility. Combining them in one bottle simplifies the ritual but locks in the ratio. If you want to experiment with the CBG to CBD ratio, two separate oils are a better choice. According to the Russo and Gardiner survey (Cannabis Cannabinoid Res, 2021), 58% advanced consumers prefer separate formulations.

How long does it take to notice the effects of a CBD plus CBG stack?

Subtle effects can be felt within 30-90 minutes, but a stable therapeutic response develops after 2-4 weeks of regular supplementation. A study by Shannon et al. in the Permanent Journal (Perm J, 2019) in 72 patients with anxiety showed that most objective changes in clinical scales appeared between weeks three and four.

Can a cannabinoid stack cause a positive drug test?

Full spectrum contains up to 0.3% THC, which could theoretically lead to detectable levels in urine in sensitive tests. Broad spectrum and isolate do not carry this risk. A study by Spindle et al. (2017) in JAMA found that 21% products labeled "zero THC" contained detectable amounts, emphasizing the importance of COAs from an accredited laboratory.

Is it worth combining CBD with melatonin for sleep?

Yes, it's a combination with mild evidence support, but it's complementary rather than synergistic. Melatonin regulates circadian rhythms, CBD lowers anxiety and evening cortisol. Typical doses: 0.5-1 mg of melatonin plus 20-30 mg of CBD 30-60 minutes before bed. Chung et al. in "Sleep Medicine" (Sleep Med, 2020) described improved sleep quality in 65% subjects.

Does the entourage effect also work at low microgram doses?

Probably not in the classical sense. Most entourage effect studies use milligram doses, and the concept of cannabinoid microdosing is poorly documented. Finlay et al. (Front Pharmacol, 2020) failed to detect significant terpene synergy even at standard experimental doses, making microdosing even more difficult to scientifically justify.

comprehensive cannabinoid guide

Summary: when together, when apart?

The answer to the title question depends on the goal. For simple general support, CBD alone, at a dose of 15-25 mg, remains a reasonable starting point. For a more pronounced focus effect in the morning, CBG plus CBD 1:2 works for most users. For quality sleep, CBD plus CBN 4:1 in the evening has growing, though still limited, research support. For chronic pain, CBD plus CBG 2:1, potentially considering THC support where it is legally available under medical supervision.

Maintaining the discipline of self-observation is crucial. Test one product for 3-4 weeks, keep a journal, and compare expectations with reality. Avoid marketing hype surrounding the entourage effect when a specific cannabinoid and terpene profile is lacking. Remember that interactions with drugs metabolized by CYP450 are real and increase proportionally to the number of cannabinoids used concurrently. If you are taking prescription medications, consult your doctor or pharmacist before using this stack.

The science of the entourage effect is young and still evolving. Works by Ferber 2020, Finlay 2020, Anand 2021, and Saleska 2024 add further insights, but the overall picture remains fragmented. By following the principles of "start low, go slow," choosing products with COAs, and having realistic expectations about the effect's strength, you minimize risk and maximize the chance of finding a stack that truly meets your needs.

final reference

Author: Michał Waluk, cannabis educator and founder of the website u Bucha, publishes on cannabinoid pharmacology, practical supplementation protocols, and market analysis of CBD products in Poland.